New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - tenecteplase 40mg (recombinant) - powder for injection - 40 mg - active: tenecteplase 40mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - tenecteplase 50mg (recombinant) - powder for injection - 50 mg - active: tenecteplase 50mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - meloxicam 7.5mg - capsule - 7.5 mg - active: meloxicam 7.5mg excipient: lactose monohydrate magnesium stearate maize starch sodium citrate dihydrate

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - meloxicam 7.5mg - tablet - 7.5 mg - active: meloxicam 7.5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium citrate dihydrate - · symptomatic treatment of painful osteoarthritis (arthrosis, degenerative joint disease). · symptomatic treatment of rheumatoid arthritis. in patients for whom longer-term use may be required, treatment efficacy should be reviewed within the first month of treatment and mobic withdrawn if there is a lack of therapeutic benefit. patients on long-term treatment should be reviewed regularly, such as every three months with regards to efficacy, risk factors and the ongoing need for treatment. the decision to prescribe a selective cox-2 inhibitor should only be made after assessment of the individual patient's overall risk for developing severe adverse events e.g. history of cardiovascular, renal, or gastrointestinal disease, and after use of alternative therapies such as non-pharmacological interventions and simple analgesic therapy where these have been found to lack analgesic efficacy or to have unacceptable adverse effects.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - dipyridamole 25mg - tablet - 25 mg - active: dipyridamole 25mg excipient: magnesium stearate - indicated as an adjunct to oral anticoagulation for the prophylaxis of thromboembolism associated with mechanical prosthetic heart valves.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - dipyridamole 150mg;   - modified release capsule - 150 mg - active: dipyridamole 150mg   excipient: acacia acetone dimeticone ethanol gelatin hypromellose hypromellose phthalate isopropyl alcohol methacrylic acid copolymer povidone purified talc purified water stearic acid tartaric acid triacetin

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - dabigatran etexilate mesylate 126.83mg equivalent to dabigatran etexilate 110 mg;  ;   - capsule - 110 mg - active: dabigatran etexilate mesylate 126.83mg equivalent to dabigatran etexilate 110 mg     excipient: acacia dimeticone hyprolose hypromellose hpmc capsule size 1 - (tt70-14-2-2) purified talc tartaric acid tekprint black sw-9008 - prevention of venous thromboembolic events in patients who have undergone major orthopaedic surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - tiotropium bromide monohydrate 22.5ug equivalent 18 µg tiotropium - powder filled inhalation capsule - 18 mcg - active: tiotropium bromide monohydrate 22.5ug equivalent 18 µg tiotropium excipient: gelatin lactose monohydrate - spiriva is indicated for the long term once daily maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva reduces the frequency of exacerbations and improves exercise tolerance and health-related quality of life.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - tiotropium bromide monohydrate 3.125ug equivalent to tiotropium 2.5 µg/dose - solution for inhalation - 2.5 mcg/dose - active: tiotropium bromide monohydrate 3.125ug equivalent to tiotropium 2.5 µg/dose excipient: benzalkonium chloride disodium edetate hydrochloric acid purified water - spiriva respimat is indicated for the long term once daily maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva reduces the frequency of exacerbations and improves exercise tolerance and health-related quality of life.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 500 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.